2 Unstoppable Cannabis Stocks That Are Better Buys Than Sundial Growers fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Item 9 Labs Corp. is
a sponsor and will speak at the Benzinga Cannabis Capital Conference set to take place on February 25-26, 2021.
The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
The cannabis industry is having a prime moment and a promising horizon ahead. After a transformative 2020, the market is experiencing policy changes worldwide, rising cannabis stocks and a high demand that positions the industry for exponential growth in the coming years.
Additionally, Mergers and Acquisitions (M&A) activity is expected to increase as cannabis stock valuations are becoming more realistic. In fact, many M&As are taking place all over the industry, reinforcing this trend. For example,
TPCO Holding Corp (The Parent Company) is coming to conquer California s cannabis market proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
CURE
Pharmaceutical Holdings (OTCQB:CURR) chairman William Yuan is transitioning to Chairman Emeritus and will remain in the company as a key advisor.
Rubén José King-Shaw Jr, who serves on the company’s board, opted to replace Yuan.
King-Shaw brings over thirty years of experience in healthcare technology and also private equity sectors.
Currently, he serves as CSO of Steward Health Care Systems, LLC.
In addition, the company appointed Dov Szapiro to its board. He serves as co-founder, managing partner and principal of Entourage Effect Capital.
“We thank Mr. Yuan for his dedicated leadership of CURE’s Board of Directors, and we are honored to have him stay with us as Chairman Emeritus and Key Advisor to the Board and executive team, as he leads the Company in its continued progress for dynamic international expansion and global revenue traction,” CURE chief executive Rob Davidson noted.
Author Bio
A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and investment planning. You ll often find him writing about Obamacare, marijuana, drug and device development, Social Security, taxes, retirement issues and general macroeconomic topics of interest. Follow @TMFUltraLong
To say that things have been interesting on Wall Street over the past three and a half weeks would be an understatement.
Following a year of historic volatility, 2021 is attempting to one-up its predecessor, with retail investors to blame. The recent battle between retail investors on the Reddit-based WallStreetBets forum and institutional money managers in heavily shorted stocks and/or companies with penny stock-level share prices has whipsawed more than a dozen momentum stocks.